Biglycan: an emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance
- 28 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular and Cellular Biochemistry
- Vol. 476 (11), 3935-3950
- https://doi.org/10.1007/s11010-021-04216-z
Abstract
Extracellular matrix (ECM) plays an important role in the structural organization of tissue and delivery of external cues to the cell. Biglycan, a class I small leucine-rich proteoglycans (SLRP), is a key component of the ECM that participates in scaffolding the collagen fibrils and mediates cell signaling. Dysregulation of biglycan expression can result in wide range of clinical conditions such as metabolic disorder, inflammatory disorder, musculoskeletal defects and malignancies. In this review, we aim to update our current understanding regarding the link between altered expression of biglycan and different clinicopathological states. Biglycan interacts with toll like receptors (TLR)-2 and TLR-4 on the immune cells which initiates inflammation and aggravates inflammatory disorders. ECM unbound soluble biglycan acts as a DAMP (danger associated molecular pattern) resulting in sterile inflammation. Dysregulation of biglycan expression is also observed in inflammatory metabolic conditions such as atherosclerosis and obesity. In cancer, high-biglycan expression facilitates tumor growth, invasion and metastasis which is associated with poor clinical outcome. As a pivotal structural component of the ECM, biglycan strengthens the musculoskeletal system and its absence is associated with musculoskeletal defects. Thus, SLRP biglycan is a potential marker which is significantly altered in different clinicopathological states.Keywords
This publication has 102 references indexed in Scilit:
- Arterial Retention of Remnant Lipoproteins Ex Vivo Is Increased in Insulin Resistance Because of Increased Arterial Biglycan and Production of Cholesterol‐Rich Atherogenic Particles That Can Be Improved by Ezetimibe in the JCR:LA‐ cp RatJournal of the American Heart Association, 2012
- Adipose tissue biglycan as a potential anti-inflammatory target of sodium salicylate in mice fed a high fat dietJournal of Inflammation, 2012
- Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cellsBritish Journal of Cancer, 2012
- Pathophysiological Mechanisms of Autosomal Dominant Congenital Stromal Corneal Dystrophy: C-Terminal–Truncated Decorin Results in Abnormal Matrix Assembly and Altered Expression of Small Leucine-Rich ProteoglycansThe American Journal of Pathology, 2011
- Serum Amyloid A Facilitates the Binding of High-Density Lipoprotein From Mice Injected With Lipopolysaccharide to Vascular ProteoglycansArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat dietJournal of Inflammation, 2011
- Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx miceProceedings of the National Academy of Sciences of the United States of America, 2010
- The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritisJCI Insight, 2010
- Biglycan, a Danger Signal That Activates the NLRP3 Inflammasome via Toll-like and P2X ReceptorsJournal of Biological Chemistry, 2009
- Biological Functions of the Small Leucine-rich Proteoglycans: From Genetics to Signal TransductionOnline Journal of Public Health Informatics, 2008